For many drugs, synthesis of the active pharmaceutical ingredient (API) represents the most economically important and technically demanding element of pharmaceutical manufacturing. Therefore, improving manufacturing efficiency represents an important step towards cost-effective access to healthcare and enhanced security of sources of supply globally. The Medicines for All Institute has developed a series of core principles that yield dramatic improvements in chemical efficiency and lowering the cost of API manufacturing processes. The Institute’s new chemical process technologies address cost savings across three major areas: high cost of starting materials, high solvent consumption, and inflexible manufacturing processes.
What stakeholders will learn from the talk:
• The Medicines for All Institute’s core competency in chemical process development for APIs demonstrate that cost savings can be made to reduce the price of treatments.
• The chemical processes developed by the Medicines for All Institute also contribute to the sustainability of the manufacturing process by introducing greener processes which is rapidly becoming an important factor for raw material suppliers.
• By offering alternative routes and strategies for producing starting materials, key intermediates, and APIs, these multiple options enable more suppliers to enter into these markets, strengthening the supply chain.
• The Medicines for All Institute also offers alternative strategies that leverage innovative technology platforms, including continuous processing, that can expand the number of suppliers for a particular market.
Speaker: Eugene Choi, Ph.D, Executive Director, Medicines for All Institute, Virginia Commonwealth University